article thumbnail

Krystexxa Chronic Gout Medication Gets Expanded FDA Approval

XTalks

Over time, even the use of Krystexxa can lead to the development of antibodies against it, reducing its effectiveness. Early data also showed that methotrexate could prevent the formation of anti-drug antibodies. Related: Vtama (tapinarof) Cream Gains FDA Approval for the Treatment of Plaque Psoriasis in Adults.

article thumbnail

GSK’s Injectable HIV Treatment Cabenuva Garners FDA Approval

XTalks

Although TaiMed Biologics’ antibody drug Trogarzo is an intravenous formulation that is administered once every 14 days, it must be used in conjunction with other antiretroviral drugs. Patients in the studies were virologically suppressed (HIV-1 RNA less than 50 copies/milliliter) prior to initiation of treatment with Cabenuva.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DDW top reads in 2023

Drug Discovery World

Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

New FDA-Approved Treatments For HIV HIV treatment involves the administration of combined antiretroviral therapy (ART) to effectively suppress the viral load, maintain or enhance immune function and reduce the risk of opportunistic infections and cancers commonly associated with HIV. aiming to end the HIV epidemic by 2030.

article thumbnail

LabCorp’s Innovative High-Speed COVID-19 Test Gets Emergency Use Authorization from the FDA

XTalks

While the new test is based on RT-PCR molecular detection, it utilizes a high-throughput technique involving a new heat-based extraction method and enhanced technology to extract RNA from samples for COVID-19 testing. LabCorp was given the green light for the test by the FDA last week, which is set to be rolled out soon.

Reagent 98
article thumbnail

Novartis bags elusive US approval for cholesterol drug inclisiran

pharmaphorum

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year. Praluent meanwhile – which also made its debut in 2015 – is faring less well, bringing in €59 million ($67 million) for Sanofi and $45 million for Regeneron in the same period.

Drugs 104
article thumbnail

AZ chases after PCSK9 rivals with antisense drug

pharmaphorum

.” Strong efficacy data is likely to be the key to carving out a role for the antisense drug in the PCSK9 inhibitor class, particularly as it is up against some heavyweight competition – notably Novartis’ small interfering RNA (siRNA) therapy Leqvio (inclisiran), which only needs to be administered twice a year.

Drugs 52